MX2018004517A - Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak). - Google Patents

Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak).

Info

Publication number
MX2018004517A
MX2018004517A MX2018004517A MX2018004517A MX2018004517A MX 2018004517 A MX2018004517 A MX 2018004517A MX 2018004517 A MX2018004517 A MX 2018004517A MX 2018004517 A MX2018004517 A MX 2018004517A MX 2018004517 A MX2018004517 A MX 2018004517A
Authority
MX
Mexico
Prior art keywords
ethoxyethoxy
imidazo
pyridin
derivatives
amino
Prior art date
Application number
MX2018004517A
Other languages
English (en)
Inventor
Jeanne Marie Menet Christel
Christophe Xavier Brys Reginald
Mammoliti Oscar
Emiel Van Der Plas Steven
Georges Pierre- Olivier DOYON Julien
Jean Joël Geney Raphaël
Marie Joncour Agnès
Michel Lefrancois Jean-
Antoine Schmitt Benoît
Gilbert Labéguère Frédéric
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2018004517A publication Critical patent/MX2018004517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe compuestos de acuerdo con la Fórmula I: (ver Fórmula) en donde R1, R2, y Cy son como se definen en el presente documento. La presente invención se refiere a compuestos que inhiben las cinasas de la familia IRAK, métodos para su producción, composiciones farmacéuticas que comprenden los mismos, y métodos de tratamiento que utilizan los mismos, para la profilaxis y/o tratamiento de enfermedades inflamatorias, enfermedades autoinmunes y/o enfermedades proliferativas mediante la administración del compuesto de la invención.
MX2018004517A 2015-10-19 2016-10-14 Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak). MX2018004517A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518456.7A GB201518456D0 (en) 2015-10-19 2015-10-19 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
PCT/EP2016/074662 WO2017067848A1 (en) 2015-10-19 2016-10-14 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors

Publications (1)

Publication Number Publication Date
MX2018004517A true MX2018004517A (es) 2018-06-27

Family

ID=55131239

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004517A MX2018004517A (es) 2015-10-19 2016-10-14 Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak).

Country Status (18)

Country Link
US (1) US10508111B2 (es)
EP (1) EP3365341B1 (es)
JP (1) JP2018530617A (es)
KR (1) KR20180064528A (es)
CN (1) CN108137584A (es)
AR (1) AR106384A1 (es)
AU (1) AU2016343225A1 (es)
BR (1) BR112018007392A2 (es)
CA (1) CA3002255A1 (es)
CO (1) CO2018004765A2 (es)
GB (1) GB201518456D0 (es)
IL (1) IL258707A (es)
MX (1) MX2018004517A (es)
PH (1) PH12018500827A1 (es)
RU (1) RU2018117499A (es)
SG (1) SG11201803095UA (es)
TW (1) TW201718582A (es)
WO (1) WO2017067848A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
GB201702603D0 (en) * 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28506A1 (es) * 2003-09-12 2005-04-29 Basf Ag 6-halógeno-(1,2,4)triazolo(1,5-a)pirimidinas para combatir plagas animales.
BRPI0506817A (pt) * 2004-01-12 2007-05-29 Cytopia Res Pty Ltd inibidores seletivos de quinase
WO2012107465A1 (en) * 2011-02-09 2012-08-16 F. Hoffmann-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
EP3049086A4 (en) * 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak inhibitors and uses thereof
UY35935A (es) * 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4

Also Published As

Publication number Publication date
US10508111B2 (en) 2019-12-17
EP3365341A1 (en) 2018-08-29
RU2018117499A (ru) 2019-11-21
PH12018500827A1 (en) 2018-10-29
CA3002255A1 (en) 2017-04-27
KR20180064528A (ko) 2018-06-14
WO2017067848A1 (en) 2017-04-27
GB201518456D0 (en) 2015-12-02
IL258707A (en) 2018-06-28
AU2016343225A1 (en) 2018-05-10
CO2018004765A2 (es) 2018-07-19
SG11201803095UA (en) 2018-05-30
US20180305351A1 (en) 2018-10-25
RU2018117499A3 (es) 2020-01-24
JP2018530617A (ja) 2018-10-18
TW201718582A (zh) 2017-06-01
CN108137584A (zh) 2018-06-08
AR106384A1 (es) 2018-01-10
EP3365341B1 (en) 2020-05-13
BR112018007392A2 (pt) 2018-10-16

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PH12018500827A1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
PH12017501921A1 (en) Novel compounds
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
MX2019003605A (es) Formas solidas de un inhibidor de cdk4/6 selectivo.
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
MX2016007371A (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
NZ749911A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
TR201907590T4 (tr) Ssao inhibitörleri olarak imidazo[4,5-c]piridin ve pirrolo[2,3-c]piridin türevleri.
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
CR20210456A (es) Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12018500796A1 (en) Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
PH12016500173A1 (en) Derivatives of 1 h-pyrazolo[3,4-b]pyridine and pharmaceutical compositions thereof for the treatment of proliferative disorders
MX2017003016A (es) Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas.
MX2018004879A (es) Nuevos derivados de piridona y su uso como inhibidores de quinasas.
MY192305A (en) Bipyrazole derivatives as jak inhibitors
MY193381A (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors